CERO THERAPEUTICS HOLDINGS, INC. (CERO)
Data as of , from SEC Form 4 filings.
See up to 3 months of CERO. The 7-day demo opens the 1M and 3M ranges and puts CERO on your watchlist.
Start 7-day demoLatest CERO insider trades
About CERO THERAPEUTICS HOLDINGS, INC. (CERO)
The SEC lists CERO THERAPEUTICS HOLDINGS, INC. under CIK 0001870404, in biological products (no diagnostic substances). We track it alongside the rest of the Health Care sector. A registration statement was filed on 5 December 2025. No offering has priced.
CERO Form 4 activity by transaction type, last 90 days
No Form 4 activity for CERO in the last 90 days.
CERO insider transactions (Form 4)
3928 Form 4 filings on record, the earliest from Oct 2, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
 Eric Francois - Director | Grant or award | Stock Option (Right to Buy) | 1,823,278 | $0.00 | - | |
| Lindsey Rolfe - Director | Grant or award | Stock Option (Right to Buy) | 690,900 | $0.00 | - | |
| Kathleen Laporte - Director | Grant or award | Stock Option (Right to Buy) | 690,900 | $0.00 | - | |
| Kristen Pierce - Officer | Grant or award | Stock Option (Right to Buy) | 1,612,099 | $0.00 | - | |
| Shami Patel - Director | Grant or award | Stock Option (Right to Buy) | 690,900 | $0.00 | - | |
| Brian G. Atwood - Director | Grant or award | Stock Option (Right to Buy) | 1,612,099 | $0.00 | - | |
| Christopher B. Ehrlich - Officer | Grant or award | Stock Option (Right to Buy) | 4,530,997 | $0.00 | - | |
| Michael Byrnes - Director | Grant or award | Stock Option (Right to Buy) | 690,900 | $0.00 | - | |
| Andrew Albert Kucharchuk - Officer | Grant or award | Stock Option (Right to Buy) | 1,162,099 | $0.00 | - | |
| Christopher B. Ehrlich - Officer | Grant or award | Stock Option (Right to Buy) | 61,843 | $0.00 | - | |
| Brian G. Atwood - Director | Grant or award | Stock Option (Right to Buy) | 122,549 | $0.00 | - | |
| Kathleen Laporte - Director | Grant or award | Stock Option (Right to Buy) | 9,326 | $0.00 | - | |
| Brian G. Atwood - Director | Option exercise | Common Stock | 294,460 | $0.00 | $29 | |
| Brian G. Atwood - Director | Option exercise | Pre-Funded Warrant | 294,460 | $0.00 | $29 | |
| YK Bioventures Opportunities GP I, LLC | Open-market sale | Common Stock | 1,343,801 | $0.08 | $108K | |
| YK Bioventures Opportunities GP I, LLC | Open-market sale | Common Stock | 1,614,541 | $0.07 | $113K | |
| YK Bioventures Opportunities GP I, LLC | Open-market sale | Common Stock | 2,998,908 | $0.06 | $180K | |
| YK Bioventures Opportunities GP I, LLC | Open-market sale | Common Stock | 1,236,874 | $0.12 | $148K | |
| YK Bioventures Opportunities GP I, LLC | Open-market sale | Common Stock | 850,543 | $0.11 | $94K | |
| YK Bioventures Opportunities GP I, LLC | Open-market sale | Common Stock | 1,570,947 | $0.09 | $141K | |
| Lindsey Rolfe - Director | Grant or award | Stock Option (Right to Buy) | 127,500 | $0.00 | - | |
| Michael Byrnes - Director | Grant or award | Stock Option (Right to Buy) | 127,500 | $0.00 | - | |
| Shami Patel - Director | Grant or award | Stock Option (Right to Buy) | 127,500 | $0.00 | - | |
| Christopher B. Ehrlich - Officer | Grant or award | Stock Option (Right to Buy) | 1,275,000 | $0.00 | - | |
| Brian G. Atwood - Director | Grant or award | Stock Option (Right to Buy) | 254,000 | $0.00 | - | |
| Kathleen Laporte - Director | Grant or award | Stock Option (Right to Buy) | 127,500 | $0.00 | - | |
| Stuart M. Sloan - 10% Owner | Open-market sale | Common Stock, $0.0001 par value per share | 532,486 | $0.10 | $56K | |
| YK Bioventures Opportunities GP I, LLC | Open-market sale | Common Stock | 3,250,000 | $0.10 | $325K | |
| Kristen Pierce - Officer | Grant or award | Stock Option (Right to Buy) | 200,000 | $0.00 | - | |
| Andrew Albert Kucharchuk - Officer | Grant or award | Stock Option (Right to Buy) | 500,000 | $0.00 | - | |
| Christopher B. Ehrlich - Officer | Option exercise | Common Stock | 5,312,983 | - | - | |
| Christopher B. Ehrlich - Officer | Option exercise | Series A Convertible Preferred Stock | 275 | $1,000.00 | $275K | |
| Christopher B. Ehrlich - Officer | Derivative | Stock Option (Right to Buy) | 572,182 | $0.00 | - | |
| Brian G. Atwood - Director | Option exercise | Common Stock | 19,358,578 | - | - | |
| Brian G. Atwood - Director | Option exercise | Series A Convertible Preferred Stock | 1,002 | $1,000.00 | $1.00M | |
| Brian G. Atwood - Director | Derivative | Stock Option (Right to Buy) | 13,857 | $0.00 | - | |
| Brian G. Atwood - Director | Derivative | Stock Option (Right to Buy) | 1,317,956 | $0.00 | - | |
| Kathleen Laporte - Director | Option exercise | Common Stock | 965,997 | - | - | |
| Kathleen Laporte - Director | Option exercise | Series A Convertible Preferred Stock | 50 | $1,000.00 | $50K |
CERO insider trading FAQ
What is the latest insider trade for CERO?
CERO THERAPEUTICS HOLDINGS, INC. (CERO) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-04-21. The full record for CERO runs to 28 Form 4 filings, the earliest from 2024-10-02. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying CERO stock?
No insider purchases of CERO were filed in the last 90 days.
How many insiders are selling CERO stock?
No insider sales of CERO were filed in the last 90 days. 8 sales are on record for this company.
Where can I see CERO SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects CERO Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Eric Francois view on EDGAR
- - Lindsey Rolfe view on EDGAR
- - Kathleen Laporte view on EDGAR
- - Kristen Pierce view on EDGAR
- - Shami Patel view on EDGAR
- - Brian G. Atwood view on EDGAR
- - Christopher B. Ehrlich view on EDGAR
- - Michael Byrnes view on EDGAR
- - Andrew Albert Kucharchuk view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where CERO's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow CERO with a 7-day demo
- CERO on your watchlist
- Every CERO Form 4 filing on record
- Up to 3 months of CERO price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
